THE EFFECT OF THE PLASMA-LEVELS OF PROTEIN-C AND PROTEIN-S ON THE PREDICTION OF WARFARIN MAINTENANCE DOSE REQUIREMENTS

被引:3
作者
LUBETSKY, A
SELIGSOHN, U
EZRA, D
HALKIN, H
机构
[1] CHAIM SHEBA MED CTR, DEPT MED A, IL-52621 TEL HASHOMER, ISRAEL
[2] TEL AVIV UNIV, ICHILOV HOSP, INST HEMATOL, IL-69978 TEL AVIV, ISRAEL
[3] TEL AVIV UNIV, SACKLER SCH MED, TEL AVIV, ISRAEL
关键词
D O I
10.1038/clpt.1992.101
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Determination of the effects of the vitamin K-dependent anticoagulants, proteins C and S, on warfarin dose requirements and on the prediction error of a bayesian warfarin dose predicting program. Methods: Patients in the study were consecutive inpatients (n = 18) starting treatment with warfarin who were monitored as outpatients for 4 weeks. The following measurements were taken: repeated (n = 8) prothrombin times, expressed as the international normalized ratio (INR), plasma protein C and S antigen levels (percentage of pooled normal plasma), demographic, clinical and biochemical variables. Results: Maintenance doses (adjusted to INR 2.5) were 6.7 +/- 3.4 mg/day. Protein C decreased to 56.9% +/- 15.3%, protein S to 63.7% +/- 17.3%, INR increased to 2.46 +/- 0.14. Prediction error decreased from 2.84 +/- 2.0 mg/day to 0.95 +/- 0.78 mg/day. Protein C accounted for only 4.2% of the mean maintenance dose but protein C and S levels accounted for 31% of the mean dose prediction error. Conclusion: Protein C and S levels affect warfarin doses and predictions significantly but not to a clinically meaningful degree.
引用
收藏
页码:42 / 49
页数:8
相关论文
共 37 条
[21]  
OREILLY RA, 1980, NEW ENGL J MED, V303, P160
[22]  
OVESEN L, 1989, EUR J CLIN PHARMACOL, V37, P573
[23]  
PORTER RS, 1986, APPLIED PHARMACOKINE, P1057
[24]   PROTEIN-C AND PROTEIN-S - VITAMIN-K-DEPENDENT INHIBITORS OF BLOOD-COAGULATION [J].
RICK, ME .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (05) :701-703
[25]  
SAWYER WT, 1985, CLIN PHARMACY, V4, P440
[26]   AGE AS A DETERMINANT OF SENSITIVITY TO WARFARIN [J].
SHEPHERD, AMM ;
HEWICK, DS ;
MORELAND, TA ;
STEVENSON, IH .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 4 (03) :315-320
[27]   CLINICAL PHARMACOKINETIC CONSIDERATIONS IN THE CONTROL OF ORAL ANTICOAGULANT-THERAPY [J].
SHETTY, HGM ;
FENNERTY, AG ;
ROUTLEDGE, PA .
CLINICAL PHARMACOKINETICS, 1989, 16 (04) :238-253
[28]   BAYESIAN PHARMACOKINETIC PHARMACODYNAMIC FORECASTING OF PROTHROMBIN RESPONSE TO WARFARIN THERAPY - PRELIMINARY EVALUATION [J].
SVEC, JM ;
COLEMAN, RW ;
MUNGALL, DR ;
LUDDEN, TM .
THERAPEUTIC DRUG MONITORING, 1985, 7 (02) :174-180
[29]   A HISTOCHEMICAL-DEMONSTRATION OF CALCIUM IN THE MATURATION STAGE ENAMEL ORGAN OF RAT INCISORS [J].
TAKANO, Y ;
MATSUO, S ;
WAKISAKA, S ;
ICHIKAWA, H ;
NISHIKAWA, S ;
AKAI, M .
ARCHIVES OF HISTOLOGY AND CYTOLOGY, 1988, 51 (03) :241-248
[30]   MULTIPLE-DOSE KINETICS OF ORAL ANTICOAGULANTS - METHODS OF ANALYSIS AND OPTIMIZED DOSING [J].
THEOFANOUS, TG ;
BARILE, RG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1973, 62 (02) :261-266